Literature DB >> 19117606

Endogenous inhibitors of angiogenesis: a historical review.

Domenico Ribatti1.   

Abstract

Under physiological conditions, angiogenesis is regulated by the local balance between endogenous stimulators and inhibitors of this process. In pathological states such as chronic inflammation and tumor growth, there is an imbalance between endogenous stimulator and inhibitor levels, leading to an "angiogenic switch". Various inhibitors of angiogenesis, including angiostatin, endostatin and thrombospondins, are found in the body. It is uncertain why the body possesses so many inhibitors, and also how these inhibitors interact to overcome the effects of angiogenesis stimulators. This review summarizes the present knowledge about endogenous inhibitors of angiogenesis.

Entities:  

Mesh:

Year:  2008        PMID: 19117606     DOI: 10.1016/j.leukres.2008.11.019

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  49 in total

1.  Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts.

Authors:  Celina Edelstein; Ditta Pfaffinger; Ming Yang; John S Hill; Angelo M Scanu
Journal:  Biochim Biophys Acta       Date:  2010-03-24

Review 2.  Tumor angiogenesis: molecular pathways and therapeutic targets.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

4.  Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factor.

Authors:  Jose L Orgaz; Alberto Benguria; Cristina Sanchez-Martinez; Omar Ladhani; Olga V Volpert; Benilde Jimenez
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

5.  CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation.

Authors:  An-Chi Tsai; Shiow-Lin Pan; Hui-Lung Sun; Chih-Ya Wang; Chieh-Yu Peng; Shih-Wei Wang; Ya-Ling Chang; Sheng-Chu Kuo; Kuo-Hsiung Lee; Che-Ming Teng
Journal:  J Biol Chem       Date:  2009-12-11       Impact factor: 5.157

6.  Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.

Authors:  Radu O Minea; Corey M Helchowski; Samuel J Zidovetzki; Fritz K Costa; Stephen D Swenson; Francis S Markland
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

7.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

8.  Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation.

Authors:  Gabriela Vazquez Rodriguez; Carmen Gonzalez; Antonio De Leon Rodriguez
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 9.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Authors:  Mark W Kieran; Raghu Kalluri; Yoon-Jae Cho
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 10.  Controlling escape from angiogenesis inhibitors.

Authors:  Barbara Sennino; Donald M McDonald
Journal:  Nat Rev Cancer       Date:  2012-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.